Cargando…
Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin...
Autores principales: | Stott Bond, Nicole L., Dréau, Didier, Marriott, Ian, Bennett, Jeanette M., Turner, Michael J., Arthur, Susan T., Marino, Joseph S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615566/ https://www.ncbi.nlm.nih.gov/pubmed/34829914 http://dx.doi.org/10.3390/biomedicines9111685 |
Ejemplares similares
-
Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line
por: Bond, Nicole L. Stott, et al.
Publicado: (2022) -
Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
por: Iglay, Kristy, et al.
Publicado: (2019) -
Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010) -
Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
por: Takahashi, Hiroshi, et al.
Publicado: (2018) -
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)